Acrivon Therapeutics Inc (ACRV)
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
📉 **NEGATIVE** • Low confidence analysis (39%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical